203 related articles for article (PubMed ID: 35674872)
21. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma.
Wang D; Xu Y; Goldstein JB; Ye K; Hu X; Xiao L; Li L; Chang L; Guan Y; Long G; He Q; Yi X; Zhang J; Wang Z; Xia X; Zhou L
Liver Int; 2020 Aug; 40(8):1997-2007. PubMed ID: 32279416
[TBL] [Abstract][Full Text] [Related]
22. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives.
Bardol T; Pageaux GP; Assenat E; Alix-Panabières C
Clin Chem; 2024 Jan; 70(1):33-48. PubMed ID: 37962158
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
27. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma.
Wang ZX; Jiang CP; Cao Y; Zhang G; Chen WB; Ding YT
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):178-85. PubMed ID: 25865691
[TBL] [Abstract][Full Text] [Related]
28. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
[TBL] [Abstract][Full Text] [Related]
29. Serum Insulin-Like Growth Factor-1 (IGF-1): a Novel Prognostic Factor for Early Recurrence of Hepatocellular Carcinoma (HCC).
Yao Y; Mao W; Dong M; Yang D; Li W; Chen Y
Clin Lab; 2017 Feb; 63(2):261-270. PubMed ID: 28182337
[TBL] [Abstract][Full Text] [Related]
30. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
31. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
[TBL] [Abstract][Full Text] [Related]
32. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
[TBL] [Abstract][Full Text] [Related]
33. Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.
Choi GH; Kim GI; Yoo JE; Na DC; Han DH; Roh YH; Park YN; Choi JS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1444-52. PubMed ID: 25791790
[TBL] [Abstract][Full Text] [Related]
34. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.
Xu Y; Cai J; Zhong K; Wen Y; Cai L; He G; Liao H; Zhang C; Fu S; Chen T; Cai J; Zhong X; Chen C; Huang M; Cheng Y; Pan M
Front Oncol; 2023; 13():1119744. PubMed ID: 36959801
[TBL] [Abstract][Full Text] [Related]
35. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score.
Zhao WH; Ma ZM; Zhou XR; Feng YZ; Fang BS
World J Gastroenterol; 2002 Apr; 8(2):237-42. PubMed ID: 11925599
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
37. Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection.
Liu WR; Tian MX; Tang Z; Fang Y; Zhou YF; Song SS; Jiang XF; Wang H; Tao CY; Zhou PY; Qu WF; Ding ZB; Peng YF; Zhou J; Fan J; Shi YH
Br J Cancer; 2020 Jul; 123(1):92-100. PubMed ID: 32376890
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
39. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma.
Umeda S; Kanda M; Sugimoto H; Tanaka H; Hayashi M; Yamada S; Fujii T; Takami H; Niwa Y; Iwata N; Tanaka C; Kobayashi D; Fujiwara M; Kodera Y
BMC Cancer; 2017 Sep; 17(1):610. PubMed ID: 28863781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
